Viropil

🧾 Product Overview Table

🧬 Introduction to Viropil
Viropil is a fixed-dose combination antiretroviral therapy (ART) containing Dolutegravir, Lamivudine, and Tenofovir Disoproxil. Manufactured by Emcure Pharmaceuticals Ltd, a leading Indian pharmaceutical firm, this medication is designed for once-daily administration to treat HIV-1 infection. The synergistic combination of these three agents helps prevent viral replication, lower viral load, and improve immune function. Viropil is widely used in both resource-limited settings and private sectors due to its proven efficacy and tolerability.

🎬 Educational Video

💉 Dosage & Indications

Note: Should be taken with caution in patients with renal impairment.

⚠️ Side Effects, Warnings & Storage

• ❗ Common Side Effects: Nausea, headache, fatigue, insomnia, diarrhea
• ⚠️ Serious Side Effects: Lactic acidosis, liver toxicity, immune reconstitution syndrome
• 🧊 Storage: Store below 30°C in a dry place, away from sunlight
• 🔔 Precautions: Not recommended for patients with known hypersensitivity to any of the components

🌍 Global Availability

🔗 Related Indian Alternatives (Different Molecules in Same Category)

📚 External Medical References

• FDA – Antiretroviral Drugs
• WHO – HIV Treatment Guidelines
• NHS – HIV & AIDS Overview
• Drugs.com – Dolutegravir/Lamivudine/Tenofovir

🩺 Expert Commentary
Dr. Anita George, Infectious Diseases Consultant:
“Viropil offers a complete daily regimen in one tablet. Its integrase inhibitor component (Dolutegravir) provides rapid viral suppression, while the nucleoside analogs contribute to backbone efficacy. It’s a WHO-recommended regimen with high success rates.”

🛡️ Final Medical Disclaimer
This article is for informational purposes only. Always consult your healthcare provider before beginning or changing any treatment.